Trastuzumab's targeted therapy has become a stronghold for human epidermal growth factor receptor 2 positive breast cancer patients. This humanized monoclonal antibody binds to the extracellular juxta-membrane domain of HER2 and inhibits the proliferation and survival of HER2 dependent cancer cells. The ways by which this molecule exerts its action have been partially elucidated but several new mechanisms are being constantly identified. Several new agents are being introduced that interfere with HER2. Several new immunotherapy strategies are being introduced in order to direct the immune sys-tem against cells and tissues that aberrantly overexpressed HER2. We review the strate-gies currently adopted and those suggested against HER2 expressing tumors. © Ivyspring International Publisher.
Immune effects of trastuzumab / Nuti, Marianna; Bellati, Filippo; Visconti, Valeria; Napoletano, Chiara; Domenici, Lavinia; Caccetta, Jlenia; Zizzari, ILARIA GRAZIA; Ruscito, Ilary; RAHIMI KOSHKAKI, Hassan; BENEDETTI PANICI, Pierluigi; Rughetti, Aurelia. - In: JOURNAL OF CANCER. - ISSN 1837-9664. - STAMPA. - 2:1(2011), pp. 317-323. [10.7150/jca.2.317]
Immune effects of trastuzumab.
NUTI, Marianna;BELLATI, FILIPPO;VISCONTI, Valeria;NAPOLETANO, Chiara;DOMENICI, LAVINIA;CACCETTA, JLENIA;ZIZZARI, ILARIA GRAZIA;RUSCITO, ILARY;RAHIMI KOSHKAKI, HASSAN;BENEDETTI PANICI, PIERLUIGI;RUGHETTI, Aurelia
2011
Abstract
Trastuzumab's targeted therapy has become a stronghold for human epidermal growth factor receptor 2 positive breast cancer patients. This humanized monoclonal antibody binds to the extracellular juxta-membrane domain of HER2 and inhibits the proliferation and survival of HER2 dependent cancer cells. The ways by which this molecule exerts its action have been partially elucidated but several new mechanisms are being constantly identified. Several new agents are being introduced that interfere with HER2. Several new immunotherapy strategies are being introduced in order to direct the immune sys-tem against cells and tissues that aberrantly overexpressed HER2. We review the strate-gies currently adopted and those suggested against HER2 expressing tumors. © Ivyspring International Publisher.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
